Table 1.
Main publications of maintenance therapies in patients with PDAC.
| Study | Study type | Maintenance treatment Induction chemotherapy |
Population (n patients) | Results |
|---|---|---|---|---|
| Reure et al.11 | Retrospective | Capecitabine After 4–8 cycles of FOLFIRINOX |
30 | OS: 17 months. Survival rates: 73% at 1 year (95% CI 0.59–0.91) and 25% at 2 years (95% CI 0.13–0.50). PFS1: 5 months–PFS2: 10 months |
| Dahan et al.12 | Phase II PANOPTIMOX |
FOLFIRINOX continuous (A) versus LV5FU2 maintenance (B) versus Gem-irinotecan (C) After FOLFIRINOX |
273 | 6-month PFS: 47% (A), 44% (B), 34% (C)—4-months RR: 35% (A), 41% (B), 17% (C) PFS: 6.3 months (A), 5.7 months (B), 4.5 months (C) OS: 10.1 months (A,) 11.2 months (B), 7.3 months (C) Duration maintenance (B): 3.3 months (0.003–22.6) |
| Reni et al.13 | Phase II PACT 12 |
Observation (A) versus sunitinib (B) 37,5 mg/day After various chemotherapies combination (mainly Gem/platinum based) |
56 | A versus B: 6-month PFS: 3.6% (95% CI 0–10.6%) versus 22.2% (95% CI 6.2–38.2%; p < 0.01); 2 years OS: 7.1% (95% CI 0–16.8%) versus 22.9% (95% CI 5.8–40.0%; p = 0.11), Stable disease: 21.4% versus 51.9% (p = 0.02). |
| Petrioli et al.14 | Observational | Gem After three cycles of Gem-NabP |
37 (>70 years) | 6-month DCR: 61% (95% CI 45–77) PFS: 6.4 months (95% CI 5.4–8.3) OS: 13.4 months (95% CI 11.1–16.7). |
| Relias et al.15 | Retrospective OPTINAB |
Gem After Gem-NabP when neuropathy occurred |
27 | Gem maintenance in seven patients with grade 3 neuropathy (median delay: 4.2 months) Mean duration maintenance: 2.8 months. Reintroduction NabP in 6/7 patients. PFS2: 2.2 months (range 1–4 months). DDR: 8,2 months (8–13) and 9.4 months with reintroduction of NabP OS: 11.7 months |
| Zhang et al.16 | Phase II | S1 After six cycles of NabP plus S1 |
32 | ORR (primary objective): 53.1% Disease control rate: 87.5% PFS: 6.2 months OS: 13.6 months |
| Golan et al.17 | Phase III | Olaparib versus placebo After platinum-based chemotherapy |
154 (gBRCA1/2 mutation) | PFS: 7.4 months versus 3.8 months (HR 0.53; 95% CI 0.35–0.82; p = 0.004—OS: 18.9 months versus 18.1 months (HR 0.91; 95% CI 0.56–1.46; p = 0.68 Anemia (11%), fatigue (5%), decrease appetite (3%), abdominal pain (2%), vomiting (1%), arthralgia (1%) (with olaparib) |
DCR, disease control rate; DDR, duration of disease control; Gem, gemcitabine; NabP, nab-paclitaxel; ORR, objective response rate; OS, overall survival.